Abstract Introduction Gross’s Emotion Regulation Questionnaire is one of the most widely-used and valid questionnaires for assessing emotion regulation strategies. The validity and reliability of the Persian version have not been determined and data on its psychometric properties are not available to Iranian mental health researchers. The purpose of this study was to determine the psychometric properties of the Emotion Regulation Questionnaire in Iranian students. Methodology In this cross-sectional study, 348 students (170 males and 178 females) were selected from Shahid Beheshti University of Medical Science and Tehran University of Medical Science. The following statistical procedures were conducted: correlation coefficients, factor analysis, Cronbach’s alpha, and independent t tests. Results The results showed that men use suppression more than women (T = -2.62, p = 0.009). Cronbach’s alpha coefficients were 0.76 for the cognitive reappraisal sub-scale and 0.72 for the suppression sub-scale (excluding question 9). Six questions related to the cognitive reappraisal factor explained 30.97% of emotion regulation variance, and 3 questions related to the suppression factor explained 22.59% of emotion regulation variance. Overall, these factors explained 53.5% of emotion regulation variance. There were significant correlations between suppression and difficulties in emotion regulation, trait anxiety, and affective control. Furthermore, there was a significant correlation between cognitive reappraisal and the Five-Facet Mindfulness Questionnaire. Conclusion The results indicate that the Persian version of the ERQ is a reliable and valid instrument that can be helpful for development of further important studies of emotional regulation.

Abstract Introduction Depression is one of the most important psychiatric disorders, and the rate of recurrence is high. The heavy cost burden of depression is probably due to treatment-resistant depression. The purpose of this study was to determine the effectiveness of mindfulness-based cognitive therapy (MBCT) in patients with treatment-resistant depression (TRD). Method The present study was a quasi-experimental study conducted with twenty-four patients with treatment-resistant depression. Participants were selected by purposive sampling and randomly assigned to two groups, an experimental group and a control group. The experimental group received MBCT and antidepressants, while the control group received antidepressants only. The Hamilton and Beck Depression Inventory, Self-Compassion Scale, Thought Rumination Scale, and Mindfulness Scale were administered. The treatment program was conducted in eight sessions; with a follow-up period of one month subsequent to treatment termination. Data were analyzed using descriptive statistics (mean and standard deviation) and inferential statistics (analysis of variance for repeated measures and Bonferroni’s post-hoc test). Results The results showed that MBCT significantly reduced depression and ruminative thinking in the experimental group and also improved mediators such as mindfulness and self-compassion. Patients maintained gains over the one month follow-up period (p < 0.01). Conclusion The present study provides additional evidence for the effectiveness of MBCT for TRD.

Abstract Introduction Multiple sclerosis (MS) is a chronic medical condition that attracts particular attention because of the high risks associated with it. MS patients suffer from medical problems, depression, anxiety, and reduced hopefulness. These issues can increase the severity of the disease and treatment resistance and reduce patients’ individual and social efficacy. Mindfulness-integrated cognitive behavior therapy (MICBT) is a new approach that is being applied in chronic diseases and can be used in combination with existing treatments. Therefore, the present study investigated the efficacy of MICBT in terms of anxiety, depression, and hope in MS patients. Methods A sample of 20 patients with MS was randomly selected at Shafa Hospital in Kerman City, Iran. Patients were then assigned to one of two groups of 10 people using a random number table. The experimental group received MICBT. The control group also received the same therapy after study completion. The assessment tools used in this study included the Beck Depression Inventory-Second Edition (BDI-II), Beck Anxiety Inventory (BAI), and Miller Hope Scale (MHS). Measurements were conducted at three stages: pre-test, post-test, and follow-up. For data analysis, means and standard deviations were calculated and one-way analysis of covariance was conducted using SPSS 24. Results Compared with controls, MICBT was effective for reducing depression (P < 0.001, F = 72.55), anxiety (P < 0.001, F = 100.75). Additionally, MICBT was effective in improving hope (P < 0.001, F = 45.36). Changes were maintained in the follow-up phase. Conclusion The MICBT affects depression, anxiety and hope of MS patients. Therefore, mental health professionals can benefit from the results obtained in the present study to reduce depression and anxiety and increase hope in this group of patients. Clinical trial registration: Iranian Registry of Clinical Trials, IRCT201601030258N4.